EU reform broadens safety rules for human-derived materials
Published on 16 November 2026
A single framework replaces blood, tissues and cells rules and extends oversight into the life sciences supply chain
At a glance
From 7 August 2027, the SoHO Regulation will replace separate EU directives for blood and for tissues and cells with a directly applicable framework.
The framework extends to substances not expressly addressed by those directives, including donated human milk and intestinal microbiota.
Specified activities involving human-derived material used to manufacture medicines and medical devices, are covered.
EU quality and safety rules for human-derived materials have been divided between two directives for more than 20 year. The Blood Directive has covered human blood and blood components, while the Tissues and Cells Directive covers human tissues and cells intended for human applications. As directives, both were implemented through national legislation, resulting in a framework that could operate differently across member states.
From 7 August 2027, Regulation (EU) 2024/1938, the SoHO Regulation, will repeal and replace both directives. It uses the broader concept of a substance of human origin, meaning any substance collected from the human body, whether or not it contains living cells. Its scope includes material intended for human application and specified activities involving material collected to manufacture medicines, advanced therapy medicinal products, investigational medicines and medical devices.
Human-derived materials can therefore enter a life sciences supply chain long before the resulting product reaches a patient. The question for businesses is not simply whether they supply a human-derived treatment. It is whether they or their supply-chain partners perform regulated activities involving the underlying material.
Legislative response
Since the adoption of the directives, new human-derived materials and processing technologies have emerged, infectious-disease risks have evolved and member states have developed different approaches to oversight. The European Commission's impact assessment also identified gaps affecting newer substances and significant differences in the evidence required for innovative preparations. For businesses planning European development programmes, those differences can create uncertainty over the work required and where a preparation may be supplied.
The new framework seeks to address safety and availability together, including continuity of supplies used in downstream manufacturing. For manufacturers that rely on human-derived starting materials, continuity of supply therefore depends not only on their own production capacity, but also on reliable access to the material needed for manufacturing. The commercial value of the reform will therefore partly depend on whether more consistent oversight makes those dependencies easier to understand and manage.
The regulation looks beyond the safety of the finished preparation. Its safeguards are intended to protect both those who provide human-derived material and those who receive it. For industrial purchasers, the way material is collected, handled and traced may therefore be as relevant as whether it meets the agreed specification.
Beyond blood banks
The regulation defines a "substance of human origin" broadly as any substance collected from the human body, whether or not it contains living cells.
Intestinal microbiota, the community of microorganisms collected from the human intestinal tract, illustrates the limits of a framework covering blood, tissues and cells. The regulation expressly identifies microbiota among the newer substances covered. Its scope can extend beyond familiar blood and tissue terminology to inputs described internally as biological raw materials or process ingredients.
That does not bring every business handling a human sample into the full regime: the scope is connected to human application and specified manufacturing uses.
The regulation does not apply simply because a laboratory handles human-derived material. The SoHO Coordination Board's question and answers in September explained that research involving the application of SoHO to the human body falls within the framework, whereas research confined to laboratory or animal studies does not. However, member states must still apply equivalent voluntary and unpaid donation standards where SoHO is donated exclusively for research without human application. The intended use of the material is therefore central to determining which parts of the framework apply.
Under the new regime, the regulatory position can therefore change as a research programme develops. Human-derived material initially used only in laboratory studies may later enter a manufacturing route covered by the regulation or be used in research involving human application. The material and its procurement description may remain unchanged, but its intended use, the activities carried out by suppliers and the applicable requirements may not. Early-stage sourcing arrangements can therefore take on a different regulatory significance as a programme moves towards clinical developments.
SoHO entities and activities
A central organising concept of the regulation is the SoHO entity: an organisation established in the EU that carries out one or more regulated SoHO activities, such as donor testing, collection, storage, release or distribution. Subject to the transitional arrangements, registration is generally required before those activities begin. A private laboratory that tests donors can therefore be a SoHO entity even though it does not treat patients. By contrast, manufacturing the diagnostic test used by that laboratory does not, on its own, give the manufacturer that status.
Where several companies within a corporate group are involved, the analysis turns on the activities carried out by each legal entity, rather than the sector in which the group operates. A laboratory providing donor-testing services, for example, has a different role from the company supplying its equipment; similarly, distributing human-derived starting material is distinct from distributing the finished medicine.
These distinctions can affect the allocation of responsibilities across pharmaceutical supply chains and for medtech and diagnostics businesses. Identifying each entity's role from the outset helps to establish where the relevant obligations sit without treating the entire corporate group in the same way.
Distinct approvals and purposes
Registration, establishment authorisation and preparation authorisation serve different purposes under the new framework. Registration identifies a SoHO entity and its activities. A SoHO establishment will generally require authorisation where it carries out both processing and storage, or performs release, import or export activities, although authorities may extend this requirement to other SoHO entities in specified circumstances. A SoHO preparation authorisation, by contrast, relates to the processed preparation and its intended clinical use, rather than only to the organisation handling it.
Not every life sciences business will require all three. Where the regulation's manufacturing route applies, the requirement for a SoHO preparation authorisation is waived for material intended to be distributed for the manufacture of medical devices, medicinal products, advanced therapy medicinal products or investigational medicinal products. This waives that particular authorisation requirement, rather than an exclusion from the regulation: specified requirements continue to apply to activities such as donor assessment and testing, collection, release and, up to distribution to the manufacturer, storage, distribution, import and export. The precise allocation of responsibilities will depend on the manufacturing route and on the activities performed by each operator.
Guidance shapes implementation
The regulation sets binding standards but leaves some technical detail to guidelines. For quality management and standards protecting donors and recipients, it gives a specified role to guideline identified on the EU SoHO platform. These come from the European Directorate for the Quality of Medicines and HealthCare (EDQM) and the European Centre for Disease Prevention and Control. Alternative approaches may be available, depending on the provision, but may need to be justified or shown to provide an equivalent level of protection. The EDQM sixth-edition Tissues and Cells Guide, released in October 2026, includes dedicated chapters on intestinal microbiota and SoHO used as manufacturing starting materials. The guide provides practical detail relevant to donor assessment, collection procedures, material specifications and record-keeping.
The non-hospital guidance adopted by the SoHO Coordination Board is aimed at SoHO entities operating outside hospitals, including registries, private laboratories, clinics and private practices. It also addresses activities involving SoHO destined for the manufacture of medicines or medical devices, although it is not general compliance guidance for manufacturers that do not themselves carry out a regulated SoHO activity.
National regulators have also started issuing recommendations. In Ireland, for example, the Health Products Regulatory Authority recommends mapping activities and preparing organisational information before registration. These materials provide useful implementation support, but national administrative arrangements may differ across the EU; the regulation permits member states to adopt more stringent protective measures, subject to its conditions.
Phased changeover
The regulation provides continuity for organisations already operating under the blood, tissues and cells directives. Blood and tissue establishments holding the relevant regulatory status under those regimes before 7 August 2027 will be treated as registered SoHO entities and, initially, as authorised SoHO establishments. Their status will then require verification against the new definition of a SoHO establishment. An organisation that does not meet that definition will remain registered as a SoHO entity but will no longer be treated as an authorised SoHO establishment. These arrangements avoid requiring established operators to restart the authorisation process, but they do not exempt them from the new requirements applicable to their activities.
A separate, more limited transition applies to certain activities involving substances that were not expressly covered by the earlier directives. Qualifying activities already under way before 7 August 2027 may continue until 8 August 2028, but this does not postpone all of the new requirements: registration and the relevant donor and recipient protection standards will apply and applications for any required establishment or preparation authorisation must be submitted by 8 November 2027. The transition does not cover every activity and its availability will need to be assessed for each operation rather than assumed across an organisation or supply chain.
Any implementation planning will need to proceed on the basis that the regulation applies from 7 August 2027, with any reliance on transitional provisions clearly documented. That assessment may also need to cover contractor arrangements, existing stock and continuity of supply, rather than focusing only on the status of the principal supplier.
Osborne Clarke comment
The most useful starting point for life sciences businesses may not be whether they are a "SoHO business" captured by the regulation, but where human-derived materials enter their operations and what happens to them.
Bringing regulatory, quality and procurement teams together may help distinguish direct obligations from reliance on regulated suppliers and identify issues that could affect development or continuity of supply. The reform also provides an opportunity to sharpen supplier selection, partnering and acquisition due diligence: evidence linked to the material, its intended use and the activities performed is likely to be more informative than a generic compliance warranty.
Where a clinical or non-clinical development programme may cross regulatory boundaries, early attention to classification and innovation strategy could help avoid assumptions becoming embedded in timelines and contracts. SoHO readiness may often fit within existing supplier qualification, quality management and change-control processes, alongside the wider changes affecting the European life sciences sector, rather than requiring a separate compliance structure.